Yervoy footer

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Ariana Pelosci

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Vickie Baracos, PhD, discusses recent results that investigate cancer cachexia and how the RNome of the muscle plays a role.

Related Content

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Phase 3 data demonstrate PD-L1 positivity and BRCA mutation status as prognostic for improved overall survival regardless of treatment arm.

Nicholas James Hornstein, MD, PhD;Timothy Brown, MD;Udhayvir S. Grewal, MD

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population

Three GI cancer medical oncologists discuss the most significant abstracts in GI cancers from the 2025 ESMO Congress.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

A shorter course of radiotherapy may provide similar oncological outcomes as long-course treatment for older patients with locally advanced rectal cancer.

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH

October 27th 2025

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

Data from a phase 2 study support further development of sacituzumab tirumotecan plus pembrolizumab in metastatic castration-resistant prostate cancer.

Ariana Pelosci